A5022068410- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Ubiquitin and proteasome pathways
- Breast Implant and Reconstruction
- PARP inhibition in cancer therapy
- Medical Imaging and Pathology Studies
- Mass Spectrometry Techniques and Applications
- Glycosylation and Glycoproteins Research
- Galectins and Cancer Biology
- Cancer, Lipids, and Metabolism
- Immunotherapy and Immune Responses
- Bone health and treatments
- Advanced Biosensing Techniques and Applications
- Gestational Trophoblastic Disease Studies
- Prostate Cancer Diagnosis and Treatment
- Advanced Nanomaterials in Catalysis
- Cell death mechanisms and regulation
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Chemokine receptors and signaling
- Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Breast Cancer Treatment Studies
- Clinical practice guidelines implementation
Institute of Cancer Research
2021-2024
Royal Marsden NHS Foundation Trust
2022-2024
Royal Marsden Hospital
2019-2022
Newcastle University
2022
Stanford University
2022
University College London
2022
University of York
2022
Royal Ottawa Mental Health Centre
2019
MRC Centre for Reproductive Health
2012
Queen's Medical Centre
2012
Abstract Inflammation is a hallmark of cancer 1 . In patients with cancer, peripheral blood myeloid expansion, indicated by high neutrophil-to-lymphocyte ratio, associates shorter survival and treatment resistance across malignancies therapeutic modalities 2–5 Whether inflammation drives progression prostate in humans remain unclear. Here we show that inhibition chemotaxis can reduce tumour-elicited reverse therapy subset metastatic castration-resistant (CRPC). We higher ratio reflects...
B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed in prostate cancers (PCs). Understanding its longitudinal expression at emergence of castration resistance and association with tumour genomics are critical to the development patient selection for targeted therapies.To characterise same-patient hormone-sensitive (HSPC) castration-resistant (CRPC) PC biopsies, associating this genomics, evaluate antitumour activity an anti-B7-H3 antibody-drug conjugate (ADC) human CRPC vitro...
Abstract Prostate cancer is the most common in men and it estimated that over 350,000 worldwide die of prostate every year. There remains an unmet clinical need to improve how clinically significant diagnosed develop new treatments for advanced disease. Aberrant glycosylation a hallmark implicated tumour growth, metastasis, immune evasion. One key drivers aberrant dysregulated expression enzymes within cell. Here, we demonstrate using multiple independent cohorts glycosyltransferase enzyme...
Targeting the androgen receptor by depriving testosterone with gonadotropin-releasing hormone agonists or antagonists, surgical castration, has been backbone of metastatic prostate cancer treatment. Although most cancers initially respond to deprivation, castration-resistant evolves into a heterogeneous disease diverse drivers progression and mechanisms therapeutic resistance. Development castrate resistance phenotype is associated lethality despite recent noteworthy strides gained via...
Germline mutations in the ataxia telangiectasia mutated (ATM) gene occur 0.5–1% of overall population and are associated with tumour predisposition. The clinical pathological features ATM-mutated prostate cancer (PC) poorly defined but have been lethal PC. To report on characteristics including family history outcomes a cohort patients advanced metastatic castration-resistant PC (CRPC) who were found to germline ATM after mutation detection by initial DNA sequencing. We acquired data saliva...
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss AR expression, lineage plasticity, and transformation cancers (PCs) that exhibit phenotypes neuroendocrine or basal-like cells. anti-apoptotic protein BCL2 is upregulated in may be a therapeutic target for this aggressive PC disease subset. There unmet clinical need, therefore, clinically...
Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm facilitate target lesion selection mCRPC with sclerotic disease for subsequent CT-guided biopsies.
138 Background: Immunotherapy is an ineffective approach in molecularly unselected mCRPC, and improving patient selection for targeted treatment this setting unmet medical need. We evaluated the antitumour activity of pembrolizumab a subset selected mCRPC with putative phenotypes associated immunotherapy sensitivity. Methods: PERSEUS1 (NCT03506997) multicentre, open-label, single arm, phase II trial patients suffering from progressive on at least one approved who had following molecular...
Abstract Background There is a debate about the cost-efficiency of methotrexate for management ectopic pregnancy (EP), especially patients presenting with serum human chorionic gonadotrophin levels >1500 IU/L. We hypothesised that further experience methotrexate, and increased use guideline-based protocols, has reduced direct costs methotrexate. Methods conducted retrospective cost analysis on women treated EP in large UK teaching hospital to (1) investigate whether medical less expensive...
Abstract Background The widespread use of highly potent androgen receptor (AR) inhibitors has led to an increasing emergence AR-independent castration-resistant prostate cancer (CRPC). AR independence, typically driven by loss expression and/or trans-differentiation a neuroendocrine or basal phenotype, lacks effective therapeutic strategies. anti-apoptotic protein BCL2 is upregulated in tumours and been proposed as target for this subset advanced cancers. Objective To characterise PC,...
Investigate the laboratory, imaging and procedural factors that are associated with a tumour-positive and/or NGS-feasible CT-guided sclerotic bone lesion biopsy result in cancer patients.In total, 113 biopsies performed patients by an interventional radiologist one institution were retrospectively reviewed. Sixty-five eventually included routine blood parameters tumour marker levels recorded. Non-contrast (NC) CTs (65), contrast-enhanced (24), PET/CTs (22) within four weeks of reviewed;...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes inhibition. The current study reports on protein in advanced prostate cancer its association with RB1 loss, clinical outcome clonal dynamics during treatment a prospective trial.
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of androgen receptor, leading prostate cancer development progression. Studies investigating clinical importance BAG-1L protein expression in advanced have been limited by paucity antibodies specifically recognize long isoform. In this study, we developed validated new BAG-1L-specific antibody using multiple orthogonal methods across several cell lines with without...
Abstract Prostate cancer is the most common in men and it estimated that over 350,000 worldwide die of prostate every year. There remains an unmet clinical need to improve how clinically significant diagnosed develop new treatments for advanced disease. Aberrant glycosylation a hallmark implicated tumour growth, metastasis, immune evasion. One key drivers aberrant dysregulated expression enzymes within cell. Here, we demonstrate using multiple independent cohorts glycosyltransferase enzyme...
<h3>Background</h3> Whilst working on the adult inpatient wards at The Royal Marsden Hospital (RMH), it was noted that anti-emetics were frequently prescribed incorrectly particularly in combination (e.g. metoclopramide with domperidone, or cyclizine). We felt a quality improvement project included simple intervention involving teaching session to junior doctors anti-emetic prescribing could improve knowledge and practice. <h3>Methods</h3> Data collected from medication charts, both before...